Letter to the EditorHaploinsufficiency of A20 causes autoinflammatory and autoimmune disorders
References (9)
- et al.
Somatic reversion in dedicator of cytokinesis 8 immunodeficiency modulates disease phenotype
J Allergy Clin Immunol
(2014) - et al.
The ubiquitin modifying enzyme A20 restricts B cell survival and prevents autoimmunity
Immunity
(2010) - et al.
A20: linking a complex regulator of ubiquitylation to immunity and human disease
Nat Rev Immunol
(2012) - et al.
NF-kappaB pathway in autoinflammatory diseases: dysregulation of protein modifications by ubiquitin defines a new category of autoinflammatory diseases
Front Immunol
(2017)
Cited by (101)
Cell death
2024, CellA20 Haploinsufficiency: A Systematic Review of 177 Cases
2024, Journal of Investigative DermatologyL'haploinsuffisance de A20 : que doit connaître le clinicien?
2024, Revue de Medecine InterneRelB-deficient autoinflammatory pathology presents as interferonopathy, but in mice is interferon-independent
2023, Journal of Allergy and Clinical ImmunologyMonogenic Systemic Autoinflammatory Diseases
2022, Encyclopedia of Infection and Immunity
This work was supported by Health and Labour Sciences Research Grants for Research on Intractable Diseases from the Ministry of Health, Labour and Welfare of Japan (grant nos. 17933688 and 17933299).
Disclosure of potential conflict of interest: H. Ohnishi has received Health and Labour Sciences Research Grants. K. Imai has received a grant from the Japanese Ministry of Health, Labour and Welfare and Sony, Inc; has consultant arrangements with CSL Behring KK and Novartis Pharma KK; and has received payment for lectures from CLS Behring and the Japan Blood Products Organization. R. Nishikomori has received payment for lectures from Novartis, Inc. S. Ito has received grants from Astellas Pharma, Inc, Pfizer Japan, Inc, AbbVie GK, Eisai Co Ltd, Sumitomo Dainipponn Pharma Co Ltd, Merck Sharp & Dohme, CSL Behring, and Kyowa Hakko Kirin Co Ltd and has received payment for lectures from Astellas Pharma, Inc, Pfizer Japan, Inc, Sanofi, AbbVie GK, Eisai Co Ltd, Asahi Kasei Parma Corporation, Sumitomo Dainipponn Pharma Co Ltd, Mitsubishi Tanabe Pharma Corporation, and Zenyaku Kogyo Co Ltd. T. Heike has received a grant from the Ministry of Health, Labour, and Welfare. O. Ohara has received a grant from the Jeffrey Modell Foundation. T. Morio has received consultant fees from Novartis, Chugai Pharmaceutical, and Teijin Pharma; has received grants from Asteras, CSL Behring, and Pfizer; and has received payment for lectures from Asteras, AbbVie, CSL Behring, Dainippon Sumitomo Pharmaceutical, JBPO, Tanabe Mitsubishi Pharmaceutical, and Teijin Pharma. T. Fukao has received grants from the Japan Agency for Medical Research and Development, Health and Labour Sciences Research Grants, Sanofi, Pfizer Japan, Inc, Chugai Pharm, Astellas, and Eli Lilly Japan KK. The rest of the authors declare that they have no relevant conflicts of interest.
- ∗
These authors contributed equally to this work.